Annual Cash & Cash Equivalents
$16.29 M
-$5.53 M-25.35%
31 December 2023
Summary:
Sunshine Biopharma annual cash & cash equivalents is currently $16.29 million, with the most recent change of -$5.53 million (-25.35%) on 31 December 2023. During the last 3 years, it has risen by +$15.30 million (+1545.88%). SBFMW annual cash & cash equivalents is now -25.35% below its all-time high of $21.83 million, reached on 31 December 2022.SBFMW Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$12.21 M
+$698.91 K+6.07%
30 September 2024
Summary:
Sunshine Biopharma quarterly cash and cash equivalents is currently $12.21 million, with the most recent change of +$698.91 thousand (+6.07%) on 30 September 2024. Over the past year, it has dropped by -$6.64 million (-35.23%). SBFMW quarterly cash and cash equivalents is now -70.75% below its all-time high of $41.73 million, reached on 30 June 2022.SBFMW Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SBFMW Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -25.4% | -35.2% |
| 3 y3 years | +1545.9% | +411.5% |
| 5 y5 years | +10000.0% | +10000.0% |
SBFMW Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -25.4% | +1545.9% | -70.8% | +496.9% |
| 5 y | 5 years | -25.4% | >+9999.0% | -70.8% | >+9999.0% |
| alltime | all time | -25.4% | >+9999.0% | -70.8% | >+9999.0% |
Sunshine Biopharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $12.21 M(+6.1%) |
| June 2024 | - | $11.51 M(-34.0%) |
| Mar 2024 | - | $17.43 M(+7.0%) |
| Dec 2023 | $16.29 M(-25.4%) | $16.29 M(-13.6%) |
| Sept 2023 | - | $18.85 M(-4.5%) |
| June 2023 | - | $19.73 M(+2.3%) |
| Mar 2023 | - | $19.29 M(-11.6%) |
| Dec 2022 | $21.83 M(+967.2%) | $21.83 M(-46.2%) |
| Sept 2022 | - | $40.56 M(-2.8%) |
| June 2022 | - | $41.73 M(+216.7%) |
| Mar 2022 | - | $13.18 M(+544.3%) |
| Dec 2021 | $2.05 M(+106.6%) | $2.05 M(-14.3%) |
| Sept 2021 | - | $2.39 M(+37.5%) |
| June 2021 | - | $1.74 M(-3.4%) |
| Mar 2021 | - | $1.80 M(+81.5%) |
| Dec 2020 | $989.89 K(+2344.1%) | $989.89 K(+102.6%) |
| Sept 2020 | - | $488.71 K(+471.0%) |
| June 2020 | - | $85.59 K(+691.9%) |
| Mar 2020 | - | $10.81 K(-73.3%) |
| Dec 2019 | $40.50 K(-64.8%) | $40.50 K(-50.6%) |
| Sept 2019 | - | $81.97 K(+119.9%) |
| June 2019 | - | $37.28 K(-60.8%) |
| Mar 2019 | - | $95.13 K(-17.4%) |
| Dec 2018 | $115.22 K(+7.1%) | $115.22 K(+148.1%) |
| Sept 2018 | - | $46.43 K(+27.6%) |
| June 2018 | - | $36.40 K(-65.3%) |
| Mar 2018 | - | $104.76 K(-2.6%) |
| Dec 2017 | $107.53 K(+87.2%) | $107.53 K(-42.8%) |
| Sept 2017 | - | $188.09 K(+46.1%) |
| June 2017 | - | $128.77 K(+651.1%) |
| Mar 2017 | - | $17.14 K(-70.2%) |
| Dec 2016 | $57.45 K(+13.1%) | $57.45 K(+163.7%) |
| Sept 2016 | - | $21.79 K(-70.5%) |
| June 2016 | - | $73.92 K(-40.1%) |
| Mar 2016 | - | $123.34 K(+142.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $50.80 K(-64.6%) | $50.80 K(-59.4%) |
| Sept 2015 | - | $125.22 K(-20.4%) |
| June 2015 | - | $157.23 K(+5.7%) |
| Mar 2015 | - | $148.70 K(+3.7%) |
| Dec 2014 | $143.42 K(+359.1%) | $143.42 K(-17.5%) |
| Sept 2014 | - | $173.86 K(+352.6%) |
| June 2014 | - | $38.41 K(-45.5%) |
| Mar 2014 | - | $70.46 K(+125.5%) |
| Dec 2013 | $31.24 K(-76.4%) | $31.24 K(-56.0%) |
| Sept 2013 | - | $70.99 K(-54.7%) |
| June 2013 | - | $156.63 K(-38.8%) |
| Mar 2013 | - | $255.92 K(+92.9%) |
| Dec 2012 | $132.64 K(+118.5%) | $132.64 K(-48.1%) |
| Sept 2012 | - | $255.41 K(+303.9%) |
| June 2012 | - | $63.24 K(+64.5%) |
| Mar 2012 | - | $38.44 K(-36.7%) |
| Dec 2011 | $60.69 K(-62.6%) | $60.69 K(-66.0%) |
| Sept 2011 | - | $178.47 K(+76.3%) |
| June 2011 | - | $101.24 K(-14.2%) |
| Mar 2011 | - | $118.06 K(-27.3%) |
| Dec 2010 | $162.39 K(+44.8%) | $162.39 K(+50.2%) |
| Sept 2010 | - | $108.15 K(+563.9%) |
| June 2010 | - | $16.29 K(-44.1%) |
| Mar 2010 | - | $29.14 K(-83.8%) |
| Dec 2009 | $112.12 K(+2470.3%) | - |
| Oct 2009 | - | $179.84 K(>+9900.0%) |
| July 2009 | - | $637.00(+0.2%) |
| Apr 2009 | - | $636.00(-40.2%) |
| Jan 2009 | - | $1063.00(-46.1%) |
| Oct 2008 | - | $1974.00(-54.7%) |
| July 2008 | $4362.00(-70.7%) | $4362.00(-0.7%) |
| Apr 2008 | - | $4391.00(-10.0%) |
| Jan 2008 | - | $4880.00(-38.2%) |
| Oct 2007 | - | $7895.00 |
| July 2007 | $14.89 K | - |
FAQ
- What is Sunshine Biopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sunshine Biopharma?
- What is Sunshine Biopharma annual cash & cash equivalents year-on-year change?
- What is Sunshine Biopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly cash and cash equivalents year-on-year change?
What is Sunshine Biopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of SBFMW is $16.29 M
What is the all time high annual cash & cash equivalents for Sunshine Biopharma?
Sunshine Biopharma all-time high annual cash & cash equivalents is $21.83 M
What is Sunshine Biopharma annual cash & cash equivalents year-on-year change?
Over the past year, SBFMW annual cash & cash equivalents has changed by -$5.53 M (-25.35%)
What is Sunshine Biopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SBFMW is $12.21 M
What is the all time high quarterly cash and cash equivalents for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly cash and cash equivalents is $41.73 M
What is Sunshine Biopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, SBFMW quarterly cash and cash equivalents has changed by -$6.64 M (-35.23%)